IPF is a relentlessly progressive disease

Of idiopathic interstitial lung diseases, IPF has the worst prognosis 5

  • IPF is marked by progressive and irreversible respiratory decline 6
  • While IPF is progressive, there is no way to predict how quickly a patient will progress 6,7

 

Progression is unpredictable and can occur at any point 6,7,8

Adapted from Ley et al (2011).
*Mixed decline refers to periods of relative stability with periods of acute worsening and rapid decline.

A diagnosis of IPF is difficult for patients 9,10

  • Progression can be quick and occur without warning, leaving patients with no time to adjust 7

Although lost lung function cannot be restored, treat upon diagnosis to help preserve more lung function to delay disease progression 6,7

Perception of stability may be misleading in IPF

Symptoms alone are not an accurate way to measure disease stability 5,7    

  • Lung damage is present before patients experience progression of their symptoms 5,7
  • Underlying disease progression may continue despite the stable appearance of symptoms 7
  • As fibrosis spreads, lung function becomes more compromised 7,8

Advances have been made in the clinical management of IPF 11

  • The ATS/ERS/JRS/ALAT Clinical Practice Guideline has been updated as of 2015 11
  • An important part of managing patients with IPF is observing their disease over time and explaining how IPF progresses and the outcome of their disease 10,12

ATS=American Thoracic Society; ERS=European Respiratory Society; JRS=Japanese Respiratory Society; ALAT=Latin American Thoracic Association.

Consider treatment upon diagnosis for your patients with IPF, even when their symptoms appear to be stable 13,14

Comorbidities are commonly associated with IPF

Prevalence of select comorbidities in a general IPF patient population 15

Adapted from Collard et al (2012).
Listed comorbidities may vary in prevalence.
Excluding myocardial infarction.

Comorbidities are common in patients with IPF and may be an important consideration when developing a treatment plan 16

EXPERT PERSPECTIVE: DIAGNOSIS    

Watch Paul Noble, MD, discuss how to accurately diagnose IPF and the importance of treating upon diagnosis    

ESBRIET CLINICAL EFFICACY    

Learn how Esbriet may help your patients maintain more lung function by reducing lung function decline 

PERSONALIZED SUPPORT    

Find out how Esbriet supports your patients with education and inspiration to help them get the most out of therapy